Abstract Vascular endothelial growth factor (VEGF) plays a key role in the development of both proliferative diabetic retinopathy (PDR) and diabetic macular oedema (DMO). In recent years, anti-VEGF agents have emerged as new approaches to the treatment of these devastating diabetic complications. Although Phase III studies in the diabetic population are needed, intravitreal anti-VEGF therapy is currently being used in clinical practice. Intravitreal injection is an effective means of delivering anti-VEGF drugs to the retina. However, this is an invasive procedure associated with potentially serious complications, such as endophthalmitis or retinal detachment, which may be significant for patients requiring serial treatment over many years. In addition, although delivered within the vitreous, anti-VEGF drugs could pass into the systemic circulation, which could potentially result in hypertension, proteinuria, increased cardiovascular events and impaired wound healing. Pegaptanib, ranibizumab and bevacizumab are the currently available anti-VEGF agents. Ranibizumab and bevacizumab block all VEGF isoforms, thus impairing both physiological and pathological neovascularisation. Pegaptanib only blocks the VEGF165 isoform, and would therefore seem the best option for avoiding systemic adverse effects in diabetic patients, although this remains to be demonstrated in clinical trials. In this regard, head-to-head studies designed to evaluate not only the efficacy, but also the systemic adverse effects of these drugs in a high-risk population such as diabetic patients are warranted.
VEGF                1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Vascular_endothelial_growth_factor

diabetic                      1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Diabetes_mellitus     

VEGF                          1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Vascular_endothelial_growth_factor

isoforms                      0.9999995464987597^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Protein_isoform       

intravitreal                  1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Intravitreal_administration

cardiovascular                0.999941734659079^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Circulatory_system    

wound healing                 1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Wound_healing         

systemic circulation          0.9999999983753014^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Circulatory_system    

retina                        0.9999999999556621^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Retina                

oedema                        1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Edema                 

VEGF165                       1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Vascular_endothelial_growth_factor

macular                       0.9999466199586057^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Macula_of_retina      

Ranibizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Ranibizumab           

endophthalmitis               1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Endophthalmitis       

Vascular endothelial growth factor1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Vascular_endothelial_growth_factor

diabetic                      1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Diabetes_mellitus     

proteinuria                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Proteinuria           

clinical trials               1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Clinical_trial        

bevacizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Bevacizumab           

vitreous                      1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Vitreous_humour       

bevacizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Bevacizumab           

hypertension                  1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Hypertension          

diabetic                      1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Diabetes_mellitus     

diabetic retinopathy          1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Diabetic_retinopathy  

diabetic                      1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Diabetes_mellitus     

ranibizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Ranibizumab           

diabetic                      1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Diabetes_mellitus     

retinal detachment            1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Retinal_detachment    

